Statistics from Altmetric.com
We appreciate the interest given to our article1 by Chu and Liaw.2
Determining disease phases of patients with chronic hepatitis B (CHB) is essential for assessing patient prognosis and need for treatment. Distinguishing between the immune-tolerant and immune-active phases among patients with hepatitis B e antigen (HBeAg)-positive CHB is best determined by identifying significant necroinﬂammation and/or ﬁbrosis through liver biopsy. However, given the dynamic nature of CHB and the risks and costs of repeated liver biopsy, this recommendation may not always be realistic, especially …
Contributors G-AK and Y-SL were responsible for the concept and design of the study and the drafting of the manuscript.
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Y-SL is an advisory board member of Bayer HealthCare, Gilead Sciences and Roche and receives research funding from Bayer HealthCare and Gilead Sciences.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.